# The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency

Study · id `cardio:ct-nct06427343` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06427343](<https://clinicaltrials.gov/study/NCT06427343>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06427343

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 114 participants.

## Technical summary

Registry record NCT06427343. Randomized; single masking; primary purpose treatment. Start 2023-10-01 (actual); primary completion 2027-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 114 participants (planned count; ClinicalTrials.gov record NCT06427343, source copy `cardio:ctgov-nct06427343-2026-11-05`, retrieved 2026-11-18)
- Started: 2023-10-01 (actual) (ClinicalTrials.gov record NCT06427343, source copy `cardio:ctgov-nct06427343-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2027-08-01 (anticipated) (ClinicalTrials.gov record NCT06427343, source copy `cardio:ctgov-nct06427343-2026-11-05`, retrieved 2026-11-18)
- Completion: 2027-08-01 (anticipated) (ClinicalTrials.gov record NCT06427343, source copy `cardio:ctgov-nct06427343-2026-11-05`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06427343, source copy `cardio:ctgov-nct06427343-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06427343-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency
- Acronym: IRONDOSE
- Condition: Heart Failure
- Condition: Iron Deficiency
- Intervention (Drug): High-dose ferric derisomaltose
- Intervention (Drug): Low-dose ferric derisomaltose
- Lead sponsor: China-Japan Friendship Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: China-Japan Friendship Hospital (`cardio:org-china-japan-friendship-hospital`)

## Provenance

Content hash: 6a3ca59226bc19573a19b62f2e7de7838d864144d7994a507cf6fdf69a385803
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
